Kyushu University Academic Staff Educational and Research Activities Database
Search by Keyword How ro search
Keyword
Search Criteria
 
Detailed Search

Researcher information (To researchers) Need Help? How to update
Takahiro Maeda Last modified date：2024.04.09

Professor / Division of Precision Medicine
Research Center for Precision Medicine
Faculty of Medical Sciences


Graduate School
Department of Medicine
Graduate School of Medical Sciences


Homepage
https://kyushu-u.elsevierpure.com/en/persons/takahiro-maeda
　Reseacher Profiling Tool　Kyushu University Pure
https://precision.kyushu-u.ac.jp/en/
Academic Degree
MD., Ph.D.
Country of degree conferring institution (Overseas)
No
Field of Specialization
Hematology/Oncology
ORCID(Open Researcher and Contributor ID)
orcid.org/0000-0003-4530-6460
Total Priod of education and research career in the foreign country
15years01months
Research
Research Interests
  • Goals of our research projects are to:
    1. Identify novel targets for acute leukemia therapy.
    2. Determine molecular mechanisms underlying fetal global repression in adult erythroid cells.
    3. Determine the role of the transcription factor LRF/ZBTB7A in hematopoietic cellular differentiation.
    keyword : Acute leukemia, Sickle cell disease, Differentiation of hematopoietic lineage cells
    2016.10.
Current and Past Project
  • Hemoglobinopathies, such as sickle cell disease (SCD) and thalassemia, are among the greatest public health concerns in the world. Although new therapeutic modalities, such as gene therapy, are currently being tested, there is a pressing need for pharmacologic approaches to treat general patient populations. Our long-term goal is to develop a compound(s) that induces fetal-type globin (HbF) production by targeting the transcriptional complex regulating globin switching. The objective of this application is to determine molecular mechanisms underlying the LRF-NuRD-mediated γ-globin silencing and identify a mean(s) to target them. Our central hypothesis is that the LRF-containing NuRD complex is a potential target for HbF reactivation therapy. The rationale for the proposed research is that understanding the LRF/NuRD-mediated globin regulation will provide greater understanding of the transcriptional complex regulating γ-globin repression and facilitate development of novel therapeutic strategies for HbF induction therapy.
  • Goal of this study is to identify novel targets for leukemia therapy using a genome-wide CRISPR/Cas9 screen.
Academic Activities
Reports
 Show All Reports >>
Presentations
 Show All Presentations >>
1. Terasaki T, Semba Y, Sasaki K, Setoguchi K, Yamauchi T, Imanaga H, Nakao F, Hirabayashi S, Nogami J, Akashi K, Maeda T. , Genome-Wide CRISPR/Cas9 Screens Identify DDX19A/DDX19B As a Critical Regulator of Intrinsic Apoptosis By Regulating MCL1 mRNA Cellular Localization. , American Society of Hematology Annual Meeting, San Diego, CA, 2023.12.
2. SembaY, Yamauchi T, Nakao F, Nogami J, Canver MC, Pinello L, Bauer DE, Ogawa S, Akashi K, Maeda T., The XPO7/Npat Axis Inactivation Is a Therapeutic Vulnerability for TP53-Mutated AML. , American Society of Hematology Annual Meeting, San Diego, CA, 2023.12.
3. Takahiro Maeda, Harnessing functional genomics to uncover potential targets for AML therapy. , 日本癌学会, 2024.10.
4. Terasaki T, Semba Y, Sasaki K, Setoguchi K, Yamauchi T, Imanaga H, Nakao F, Hirabayashi S, Nogami J, Akashi K, Maeda T., Genome-Wide CRISPR-Cas9 Screens Identify DDX19A/DDX19B As a Critical Regulator of Intrinsic Apoptosis by Regulating MCL1 mRNA Cellular Localization., FASEB Hematologic Malignancies Conference, 2023.08.
5. Imanaga H, Semba Y, Sasaki K, Setoguchi K, Yamauchi T, Terasaki T, Nakao F, Hirabayashi S, Nogami J, Akashi K, Maeda T. , Autophagy Induction via mTORC1 Inhibition is an Essential Mechanism in Glucocorticoid-Mediated Cell Death in B-cell Precursor Acute Lymphoblastic Leukemia, FASEB Hematologic Malignancies Conference, 2023.08.
6. Yuichiro Semba, Takahiro Maeda, The XPO7/NPAT axis as a potential therapeutic target for TP53-mutated AML., FASEB Hematologic Malignancies Conference, 2023.08.
7. Takahiro Maeda, Identifying novel targets for AML therapy using functional genomic tools., BMT/HM Grand Rounds, Dana-Farber Cancer Institute., 2023.05.
8. Takahiro Maeda, Identifying novel combination therapies for B-ALL harboring the IgH::CRLF2 rearrangement using functional genomics tools, European School of Haematology ALL 2023, Berlin, Germany, 2023.05.
9. Hiroshi Imanaga, Yuichiro Semba, Kensuke Sasaki, Kiyoko Miyata, Takuji Yamauchi, Tatsuya Terasaki, Fumihiko Nakao, Shigeki Hirabayashi, Jumpei Nogami, Koichi Akashi, and Takahiro Maeda, Genome-wide CRISPR-Cas9 screens identify the GATOR1 complex as a critical regulator of glucocorticoid sensitivity in B-ALL, American Society of Hematology Annual Meeting, New Orleans, LA, 2022.12.
10. Yuichiro Semba, Takuji Yamauchi, Fumihiko Nakao, Jumpei Nogami, Qiuming Yao, Matthew C. Canver, Luca Pinello, Daniel E. Bauer, Seishi Ogawa, Koichi Akashi and Takahiro Maeda, The XPO7/NPAT axis is a potential therapeutic target for TP53-mutated AML, American Society of Hematology Annual Meeting, New Orleans, LA, 2022.12.
11. Sasaki K, Yamauchi T, Semba Y, Nogami J, Imanaga H, Terasaki T, Nakao F, Akahane K, Inukai T, Verhoeyen E, Akashi K and Maeda T, Genome-Wide CRISPR-Cas9 Screen Identifies Rationally Designed Combination Therapies Relevant for CRLF2-Rearranged Ph-like ALL, American Society of Hematology annual meeting, Atlanta, USA, 2021.12.
12. Yamauchi T, Miyawaki K, Semba Y, Nakao F, Nogami J, Sugio T, Sasaki K, Canver MC, Osborne S, Pinello L, Taylor D, Bauer DR, Akashi K, Maeda T., PAICS, a de novo purine synthetic enzyme, is a novel target for AML therapy., American Society of Hematology annual meeting, Orland, USA, 2019.09.
13. SembaY, Yamauchi T, Nakao F, Nogami J, Canver MC, Pinello L, Bauer DE, Akashi K, Maeda T., CRISPR-Cas9 screen identifies XPO7 as a potential therapeutic target for TP53-mutated AML., American Society of Hematology annual meeting, Orland, USA, 2019.09.
14. Nakao F, Yamauchi T, SembaY, Nogami J, Akashi K and Maeda T., CRISPR-Cas9 screen identifies Me2, a mitochondrial malic enzyme, as a molecule relevant for MCL1 inhibitor resistance in AML. American Society of Hematology annual meeting,, American Society of Hematology annual meeting, Orland, USA, 2019.09.
Membership in Academic Society
  • American Society of Hematology
  • Japanese Society of Hematology
  • Society of Hematologic Oncology
  • Japan Society for Hematopoietic Cell Transplantation
  • Japanese Cancer Association
  • Japanese Society of Internal Medicine
  • Japan Society of Transfusion Medicine and Cell Therapy


Unauthorized reprint of the contents of this database is prohibited.

Copyright © 2006, Kyushu University. All rights reserved.